Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known as “TAPI.” A prominent player in the global small-molecule API…
Grifols, a distinguished global healthcare company with a 115-year legacy as a leading manufacturer of plasma-derived medicines, has bolstered its senior management team through two strategic appointments. Dr. Roland Wandeler assumes the role of President for the Biopharma Business Unit,…
E. Merck KG Announces Results of Board Election E. Merck KG, the entity holding approximately 70 percent of Merck KGaA on behalf of the Merck family, revealed the outcomes of its routine board elections held over the weekend. Johannes Baillou…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the establishment of Regeneron Cell Medicines, marking a strategic agreement with 2seventy bio, Inc. to acquire complete development and commercialization rights to its portfolio of novel immune cell therapies. This acquisition encompasses preclinical…
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in…
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced an amendment to their collaboration agreement, along with a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. This equity…
In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth fueled by the success of Dupixent and ALTUVIIIO launches, which…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has disclosed compelling 72-week data derived from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in the treatment of macular edema stemming from branch and central retinal vein occlusion (BRVO and…
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 PROFIT AND LOSS 2023 2022 Growthas reported Growthat CER* DKK million Net sales 232,261…
ObjectiveHealth, a leading integrated specialty research network and technology company, announced today that it has secured a strategic growth investment from Vitruvian Partners, a leading global growth-focused investment firm. ObjectiveHealth is an innovator in clinical research, seamlessly integrating clinical trials…
Merck, a leading science and technology company, has signed a 10-year green power purchase agreement (PPA) with China Resources Power Holdings Co., Ltd. This is Merck’s first long-term renewable energy procurement in China, with an expected consumption of 300 gigawatt…
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple…
